Showcasing a Phase I Trial of FAP-Exd (AVA6103), a Fibroblast Activation Protein (FAP)-enabled pre|CISION® Peptide-drug Conjugate Delivering Sustained Tumour Microenvironment (TME) Release of Exatecan in Patients with FAP-positive Solid Tumours

11:30 am - Monday 8th March 2027

  • Avacta’s pre|CISION® peptide-drug conjugates are designed to selectively release potent cytotoxic payloads within the tumour microenvironment through FAP-mediated linker cleavage, with the aim of maximising tumour exposure while minimising systemic toxicity
  • AVA6103 (FAP-activated exatecan; FAP-Exd), the latest pre|CISION® peptide-drug conjugate in the clinic, is advancing through Phase 1a dose escalation, with Phase 1b expansion anticipated to commence in 2027
  • Highlighting emerging data from the AVA6103 programme, providing insights into target engagement, mechanism of action and the potential of FAP-enabled tumour-selective drug delivery in several solid-tumour types

Speakers:

Associate Director Clinical Science & Translational Medicine
Avacta Therapeutics